Aprutumab

CAS No. 1634620-63-5

Aprutumab( —— )

Catalog No. M36658 CAS No. 1634620-63-5

Aprutumab (BAY 1179470) is a human FGFR2 monoclonal antibody with affinity to FGFR2 isoforms FGFR2-IIIB and FGFR2-IIIC. Aprutumab is commonly used to synthesize antibody-drug conjugates.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 869 Get Quote
5MG 1539 Get Quote
10MG 2071 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Aprutumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Aprutumab (BAY 1179470) is a human FGFR2 monoclonal antibody with affinity to FGFR2 isoforms FGFR2-IIIB and FGFR2-IIIC. Aprutumab is commonly used to synthesize antibody-drug conjugates.
  • Description
    Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    FGFR
  • Recptor
    FGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1634620-63-5
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Anette Sommer, et al. Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors. Cancer Res (2016) 76 (21): 6331–6339.?
molnova catalog
related products
  • Sucralfate

    Sucralfate is a cytoprotective agent, an oral gastrointestinal medication primarily indicated for the treatment of active duodenal ulcers.

  • Dalcetrapib

    Dalcetrapib, a rhCETP inhibitor (IC50=0.2 μM), increases the plasma HDL cholesterol.

  • FGFR2-IN-3

    FGFR2-IN-3 is an orally active selective FGFR2 inhibitor.